Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease (Br J Surg 2009; 96: 175-184)

British Journal of Surgery

Volumn 96, Issue 7, 2009, Pages 823-

  Soreide J A ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

DISEASE FREE SURVIVAL; HUMAN; LETTER; LIVER DISEASE; LIVER METASTASIS; LIVER TRANSPLANTATION; MORTALITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL;

DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMORS;

EID: 67650022872     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6707     Document Type: Letter

References (3)

1. Søreide JA, van Heerden JA, Thompson GB, Schleck C, Ilstrup DM, Churchward M. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 2000; 24: 1431-1436.
2. Modlin IM, Kidd M, Drozdov I, Siddique ZL, Gustafsson BI. Pharmacotherapy of neuroendocrine cancers. Expert Opin Pharmacother 2008; 9: 2617-2626.
3. Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009; CD007118.